Indian J Pharm Close
 

Figure 3: (a) Pathological changes of DRGs light microscopically on week 4 in sham-operated group (b) Pathological changes of DRGs light microscopically on week 4 in saline group (c) Pathological changes of DRGs light microscopically on week 4 in saline + VEGF-antibody group (d) Pathological changes of DRGs light microscopically on week 4 in Bufl omedil group (e) Pathological changes of DRGs light microscopically on week 4 in Bufl omedil + VEGF-antibody group

Figure 3: (<b>a</b>) Pathological changes of DRGs light microscopically on week 4 in sham-operated group (<b>b</b>) Pathological changes of DRGs light microscopically on week 4 in saline group (<b>c</b>) Pathological changes of DRGs light microscopically on week 4 in saline + VEGF-antibody group (<b>d</b>) Pathological changes of DRGs light microscopically on week 4 in Bufl omedil group (<b>e</b>) Pathological changes of DRGs light microscopically on week 4 in Bufl omedil + VEGF-antibody group